CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
Key Highlights
- ➤CRISPR Therapeutics (CRSP) to present Phase 1 zugo-cel autoimmune disease data
- ➤Zugo-cel targets CD19 in refractory systemic sclerosis patients
- ➤Poster presentation scheduled for November 8, 2026, at 10:30 a.m. ET
- ➤Zugo-cel Phase 1 trials span rheumatologic, hematologic and neurologic indications
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis Session Type: Poster Presentation Abstract Number: 0225 Session Name: Poster Session A Date and Time: Sunday, November 8, 2026, 10:30 a.m. ET
Get started
Create a free account to read the full story.